Engineering lymphocyte subsets: tools, trials and tribulations.
Cell-based therapies with various lymphocyte subsets hold promise for the treatment of several diseases, including cancer and disease resulting from inflammation and infection. The ability to genetically engineer lymphocyte subsets has the potential to improve the natural immune response and correct impaired immunity. In this Review we focus on the lymphocyte subsets that have been modified genetically or by other means for therapeutic benefit, on the technologies used to engineer lymphocytes and on the latest progress and hurdles in translating these technologies to the clinic.
Department of Pathology and Laboratory Medicine and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA. cjune@exchange.upenn.edu
Carl H
CH
June
Bruce R
BR
Blazar
James L
JL
Riley
D019264:Adoptive Transfer; D000818:Animals; D002986:Clinical Trials as Topic; D044127:Epigenesis, Genetic / Q000235:genetics / Q000276:immunology; D005818:Genetic Engineering; D005822:Genetic Vectors / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D016131:Lymphocyte Subsets / Q000276:immunology* / Q000637:transplantation*; D014161:Transduction, Genetic; D019076:Transgenes / Q000235:genetics / Q000276:immunology